<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "IDArubicin, preservative free inj VIAL">
<dose><value>8</value>
<value>10</value>
<value>12</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>IDArubicin, preservative free inj VIAL</value>
</drugname><strength><value>1 mg/mL</value>
</strength><frequency><value>ONCE</value>
</frequency><instruction></instruction><volume><value>10 mL</value>
<value>5 mL</value>
</volume><units><value>mg/m2</value>
</units><additionalnotes><value>ALL, ANLL. Recommend 50%25 dose reduction in patients with serum creatinine greater than 200 umol/L. In patients with serum Bilirubin 40 to 85 umol/L, suggest 50%25 dose reduction. If serum bilirubin level is greater than 85 umol/L; suggest omit dose.</value>
<value>ALL. Recommend 50%25 dose reduction in patients with serum creatinine greater than 200 umol/L. In patients with serum Bilirubin 40 to 85 umol/L, suggest 50%25 dose reduction. If serum bilirubin level is greater than 85 umol/L; suggest omit dose.</value>
</additionalnotes><population><value>ADULT</value>
<value>CHILDREN</value>
</population><indicationprn></indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3396</value>
</backgroundinformation><prninformation></prninformation><ahsformularystatus><value>Formulary.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose></maximumprndose><din><value>02282496</value>
</din><type><value>Medication/IV Therapy</value>
</type></drug>